Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9204445 | 1.00 | CYP1A2 (0.57) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| SCHEMBL9209516 | 0.98 | CYP1A2 (0.54) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| SCHEMBL6625337 | 0.98 | CYP1A2 (0.59) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL1678031 | 0.96 | CYP1A2 (0.57) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| SCHEMBL9208675 | 0.92 | CYP1A2 (0.63) | CYP1A2SIGMAR1ALDH1A1TSHRNAAA | |
| SCHEMBL22651943 | 0.92 | SIGMAR1 (0.63) | CYP1A2SIGMAR1ALDH1A1TSHRNAAA | |
| SCHEMBL629782 | 0.92 | CYP1A2 (0.61) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| SCHEMBL12288486 | 0.92 | CYP1A2 (0.61) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| SCHEMBL22099379 | 0.92 | ALDH1A1 (0.54) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL1677793 | 0.90 | CYP1A2 (0.59) | CYP1A2SIGMAR1ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-4312861-A | Pharmaceutical compositions containing N-alkyl-N-(nuclearly-substituted) benzylamines having vasotonia-regulating activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | CYP1A2 4875/4885SIGMAR1 3483/4885ALDH1A1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.